Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2025 Jan 24:2025.01.23.634492.
doi: 10.1101/2025.01.23.634492.

A Robust Proteomics-Based Method for Identifying Preferred Protein Targets of Synthetic Glycosaminoglycan Mimetics

Affiliations

A Robust Proteomics-Based Method for Identifying Preferred Protein Targets of Synthetic Glycosaminoglycan Mimetics

Daniel K Afosah et al. bioRxiv. .

Abstract

A robust technology is critically needed for identifying preferred protein targets of glycosaminoglycans (GAGs), and synthetic mimetics thereof, in biological milieu. We present a robust 10-step strategy for identification and validation of preferred protein targets of highly sulfated, synthetic, small, GAG-like molecules using diazirine-based photoaffinity labeling-proteomics approach. Our work reveals that optimally designed, homogeneous probes based on minimalistic photoactivation and affinity pulldown groups coupled with rigorous proteomics, biochemical and orthogonal validation steps offer excellent potential to identify preferred targets of GAG mimetics from the potentially numerous possible targets that cloud GAG interaction studies. Application of this 10-step strategy for a promising highly sulfated, small GAG mimetic led to identification of only a handful of preferred targets in human plasma. This new robust strategy will greatly aid drug discovery and development efforts involving GAG sequences, or sulfated small mimetics thereof, as leads.

Keywords: glycosaminoglycan-binding proteins; glycosaminoglycans; interactome; photoaffinity; proteomics.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Structures of synthetic GAG mimetic G2.2 (A) and its photoaffinity probe G2P (B) containing diazirine and alkyne moieties (shown in red). (C) Molecular models of G2.2 (left) and G2.2 (blue) overlaid on HS06 (green) with sulfates shown in atom-type color. (D) Structure of HS06, which is functionally and structurally mimicked by G2.2.
FIGURE 2.
FIGURE 2.
(A) Synthesis of G2P from quercetin (1) in eight steps. (B) Binding and photolabeling property of G2P against two test proteases, thrombin (FIIa) and factor IXa (FIXa), of the coagulation cascade. Increasing levels of G2P levels resulted in higher photoaffinity labeling (fluorescence gels) as a proportion of the total protein (silver stained gels), which can be analyzed as hyperbolas for affinity calculations (graphs).
FIGURE 3.
FIGURE 3.
The 10-step strategy based on PAL-proteomics to identify the preferred targets of G2P, and thereby G2.2, in human plasma. Steps 1 – 4 involve PAL methods, steps 5 – 8 correspond to proteomics, and steps 9 & 10 involve validation of targets. This strategy rests on rigorous application of steps 7, 8 and 10, which focus on identifying the ‘preferred’ targets. The human plasma G2P targetome was reliably identified to contain 12 proteins (step 8) from >80 identified as plausible targets. See text for details.
FIGURE 4.
FIGURE 4.
(A) Distribution of proteins identified as preferred targets of G2P using literature reports and Cardin-Weintraub (CW) consensus sequence analysis. See also Table S5 for details. (B) Binding affinities of G2.2 for two of the representative six protein targets identified as preferred ones through PAL-proteomics. His-tagged proteins, labeled with RED-tris-NTA dye, were used in microscale thermophoresis (MST)-based titrations to measure KD of interaction. (C) Comparison MST-measured KDs for G2.2 (red) and G2P (cyan). Error bars show ±1 SE. See also Figures S5 and S6 for all profiles.

Similar articles

References

    1. Perez S, Makshakova O, Angulo J, Bedini E, Bisio A, de Paz JL, Fadda E, Guerrini M, Hricovini M, Hricovini M, Lisacek F, Nieto PM, Pagel K, Paiardi G, Richter R, Samsonov SA, Vivès RR, Nikitovic D, Ricard Blum S. Glycosaminoglycans: What remains to be deciphered? JACS Au. 2023. Mar 2;3(3):628–656. - PMC - PubMed
    1. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl. 2002. Feb 1;41(3):391–412. - PubMed
    1. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 2002;71:435–71. - PubMed
    1. Vallet SD, Berthollier C, Ricard-Blum S. The glycosaminoglycan interactome 2.0. Am J Physiol Cell Physiol. 2022. Jun 1;322(6):C1271–C1278. - PubMed
    1. Gómez Toledo A, Sorrentino JT, Sandoval DR, Malmström J, Lewis NE, Esko JD. A systems view of the heparan sulfate interactome. J Histochem Cytochem. 2021. Feb;69(2):105–119. - PMC - PubMed

Publication types

LinkOut - more resources